跳轉至內容
Merck
全部照片(4)

重要文件

B0515

Sigma-Aldrich

倍他米松 17-戊酸酯

同義詞:

9α-氟-16β-甲基-11β,17α,21-三羟基-1,4-孕甾二烯-3,20-二酮 17-戊酸盐, 9α-氟-16β-甲基氢化泼尼松 17-戊酸盐, 倍他米松戊酸盐, 倍他米松戊酸酯

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C27H37FO6
CAS號碼:
分子量::
476.58
Beilstein:
4240001
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77
暫時無法取得訂價和供貨情況

形狀

powder

起源

Schering Plough

儲存溫度

2-8°C

SMILES 字串

CCCCC(=O)O[C@@]1([C@@H](C)CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO

InChI

1S/C27H37FO6/c1-5-6-7-23(33)34-27(22(32)15-29)16(2)12-20-19-9-8-17-13-18(30)10-11-24(17,3)26(19,28)21(31)14-25(20,27)4/h10-11,13,16,19-21,29,31H,5-9,12,14-15H2,1-4H3/t16-,19?,20?,21-,24-,25-,26-,27-/m0/s1

InChI 密鑰

SNHRLVCMMWUAJD-QDHNOTTGSA-N

尋找類似的產品? 前往 產品比較指南

生化/生理作用

Betamethasone 17-valerate is a synthetic glucocorticoid. It exhibitstherapeutic effects against various allergic and inflammatory skin diseases.[1] Betamethasone 17-valerate also possesses anti-inflammatory properties.[2]

特點和優勢

This compound was developed by Schering Plough. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

象形圖

Health hazard

訊號詞

Danger

危險聲明

危險分類

Repr. 1B - STOT RE 2

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 2

個人防護裝備

Eyeshields, Gloves, type N95 (US)


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

未看到正確版本?

如果您需要一個特定的版本,您可以透過批號來尋找特定憑證。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Effect of five anti-inflammatory steroids on collagen and glycoaminoglycan synthessis in vitro
Saarni H, et al.
British Journal of Dermatology, 103(2), 167-173 (1980)
Saif-ur-Rehman Khattak et al.
AAPS PharmSciTech, 14(1), 177-182 (2012-12-20)
The effects of solvent [acetonitrile, methanol, and acetonitrile/water mixture (20:80, v/v)], buffer concentration (phosphate buffer, pH 7.5), ionic strength and commonly employed adjuvants on the photodegradation of betamethasone-17 valerate in cream and gel formulations have been studied on exposure to UV
Christine Bangert et al.
Dermatology (Basel, Switzerland), 222(1), 36-48 (2010-12-15)
Topical pimecrolimus may maintain remissions of atopic dermatitis (AD) by inhibiting subclinical inflammation. To evaluate clinical and cytological effects of pimecrolimus in topical corticosteroid-treated and resolved AD lesions. Patients (n=67) with resolved AD lesions were randomized to 3-week double-blind treatment
Jens-Michael Jensen et al.
Experimental dermatology, 20(10), 783-788 (2011-06-29)
It has been suggested that the increased rate of bacterial infection in atopic dermatitis (AD) may be caused by reduced antimicrobial protein (AMP) expression. We were interested whether common treatments in AD affect antimicrobial defense. We investigated the effects of
Prakash Adhikari et al.
International journal of pediatric otorhinolaryngology, 75(4), 500-503 (2011-02-05)
This study was carried out with the objective of comparing clinical efficacy of 10% ichthammol glycerine (IG) pack with steroid-antibiotic pack for relieving pain in cases of acute otitis externa. A prospective quasi-randomized clinical trial was completely carried out in

Questions

Reviews

No rating value

Active Filters

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務